

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## **IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 October 2002 (10.10.2002)

PCT

(10) International Publication Number  
**WO 02/078762 A1**

(51) International Patent Classification<sup>7</sup>: **A61L 31/02**,  
A61F 2/06

(21) International Application Number: PCT/US02/09297

(22) International Filing Date: 28 March 2002 (28.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/279,951 29 March 2001 (29.03.2001) US  
09/884,729 19 June 2001 (19.06.2001) US

(71) Applicant: **CORDIS CORPORATION** [US/US]; 14201  
N.W. 60th Avenue, Miami Lakes, FL 33014 (US).

(72) Inventors: **DAVILA, Luis, A.**; 3527 Ballantyne Drive,  
Pleasanton, CA 94588 (US). **MENDEZ, Jorge, O.**; 11751  
S.W. 123rd. Avenue, Miami, FL 33186 (US). **PELTON,**  
**Alan, R.**; 421 Hillview Drive, Fremont, CA 94536 (US).  
**SCHEIDT, Karl, K.**; 18185 N.W. 21st Street, Pembroke

Pines, FL 33029 (US). **SHAW JR., William, D.**; 20150  
N.E. 3rd Court, #8, Miami, FL 33179 (US). **SILVER,**  
**James, H.**; 2894 Briarfield Avenue, Redwood City, CA  
94061 (US). **TREPANIER, Christine**; 39469 Gallaudet  
Drive, Apt. 312, Fremont, CA 94538 (US). **WILSON,**  
**David, J.**; 547 Cascade Falls Drive, Ft. Lauderdale, FL  
33327 (US).


(74) Agents: **JOHNSON, Philip, S.** et al.; One Johnson &  
Johnson Plaza, New Brunswick, NJ 08903 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,  
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: **RADIOPAQUE INTRALUMINAL MEDICAL DEVICE**



(57) Abstract: A stent or other intraluminal medical device having markers formed from housings integral with the stent and marker inserts having a higher radiopacity than the stent provides for more precise placement and post-procedural visualization in a vessel, by increasing the radiopacity of the stent under X-ray fluoroscopy. The housings are formed integral to the stent and the marker inserts are made from a material close in the galvanic series to the stent material and sized to substantially minimize the effect of galvanic corrosion.

WO 02/078762 A1



European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## RADIOPAQUE INTRALUMINAL MEDICAL DEVICE

CROSS REFERENCE TO RELATED APPLICATIONS

5

This application claims the benefit of U.S. Provisional Application No. 60/279,951 filed March 29, 2001

BACKGROUND OF THE INVENTION

10

## 1. Field of the Invention

15

The present invention relates to intraluminal devices, and more particularly to intraluminal devices, such as stents, incorporating integral markers for increasing the radiopacity thereof.

## 2. Discussion of Related Art

20

25

30

Percutaneous transluminal angioplasty (PTA) is a therapeutic medical procedure used to increase blood flow through an artery. In this procedure, the angioplasty balloon is inflated within the stenosed vessel, or body passageway, in order to shear and disrupt the wall components of the vessel to obtain an enlarged lumen. With respect to arterial stenosed lesions, the relatively incompressible plaque remains unaltered, while the more elastic medial and adventitial layers of the body passageway stretch around the plaque. This process produces dissection, or a splitting and tearing, of the body passageway wall layers, wherein the intima, or internal surface of the artery or body passageway, suffers fissuring. This dissection forms a "flap" of underlying tissue which may reduce the blood flow through the lumen, or completely block the lumen. Typically, the distending intraluminal pressure within the body passageway can hold the disrupted layer, or flap, in place. If the intimal flap created by the balloon dilation procedure is not maintained in place against the

expanded intima, the intimal flap can fold down into the lumen and close off the lumen, or may even become detached and enter the body passageway. When the intimal flap closes off the body passageway, immediate surgery is necessary to correct the problem.

5           Recently, transluminal prostheses have been widely used in the medical arts for implantation in blood vessels, biliary ducts, or other similar organs of the living body. These prostheses are commonly referred to as stents and are used to maintain, open, or dilate tubular structures. An example of a commonly used stent is given in U.S. Patent No. 4,733,665 to Palmaz. Such  
10       stents are often referred to as balloon expandable stents. Typically the stent is made from a solid tube of stainless steel. Thereafter, a series of cuts are made in the wall of the stent. The stent has a first smaller diameter which permits the stent to be delivered through the human vasculature by being crimped onto a balloon catheter. The stent also has a second, expanded diameter, upon  
15       application of a radially, outwardly directed force, by the balloon catheter, from the interior of the tubular shaped member.

          However, one concern with such stents is that they are often impractical for use in some vessels such as the carotid artery. The carotid artery is easily  
20       accessible from the exterior of the human body, and is close to the surface of the skin. A patient having a balloon expandable stent made from stainless steel or the like, placed in their carotid artery, might be susceptible to severe injury through day to day activity. A sufficient force placed on the patient's neck could cause the stent to collapse, resulting in injury to the patient. In  
25       order to prevent this, self-expanding stents have been proposed for use in such vessels. Self-expanding stents act like springs and will recover to their expanded or implanted configuration after being crushed.

          One type of self-expanding stent is disclosed in U.S. Patent No.  
30       4,655,771. The stent disclosed in U.S. Patent No. 4,655,771 has a radially and axially flexible, elastic tubular body with a predetermined diameter that is variable under axial movement of the ends of the body relative to each other and which is composed of a plurality of individually rigid but flexible and elastic

thread elements defining a radially self-expanding helix. This type of stent is known in the art as a "braided stent" and is so designated herein. Placement of such stents in a body vessel can be achieved by a device which comprises an outer catheter for holding the stent at its distal end, and an inner piston which  
5 pushes the stent forward once it is in position.

However, braided stents have many disadvantages. They typically do not have the necessary radial strength to effectively hold open a diseased vessel. In addition, the plurality of wires or fibers used to make such stents  
10 could become dangerous if separated from the body of the stent, where they could pierce through the vessel. Therefore, there has been a desire to have a self-expanding stent which is cut from a tube of metal, which is the common manufacturing method for many commercially available balloon-expandable stents. In order to manufacture a self-expanding stent cut from a tube, the  
15 alloy used would preferably exhibit superelastic or psuedoelastic characteristics at body temperature, so that it is crush recoverable.

The prior art makes reference to the use of alloys such as Nitinol (Ni-Ti alloy), which have shape memory and/or superelastic characteristics, in  
20 medical devices which are designed to be inserted into a patient's body. The shape memory characteristics allow the devices to be deformed to facilitate their insertion into a body lumen or cavity and then be heated within the body so that the device returns to its original shape. Superelastic characteristics, on the other hand, generally allow the metal to be deformed and restrained in the  
25 deformed condition to facilitate the insertion of the medical device containing the metal into a patient's body, with such deformation causing the phase transformation. Once within the body lumen, the restraint on the superelastic member can be removed, thereby reducing the stress therein so that the superelastic member can return to its original un-deformed shape by the  
30 transformation back to the original phase.

Alloys having shape memory/superelastic characteristics generally have at least two phases. These phases are a martensite phase, which has a

relatively low tensile strength and which is stable at relatively low temperatures, and an austenite phase, which has a relatively high tensile strength and which is stable at temperatures higher than the martensite phase.

Shape memory characteristics are imparted to the alloy by heating the metal at a temperature above which the transformation from the martensite phase to the austenite phase is complete, i.e. a temperature above which the austenite phase is stable (the  $A_f$  temperature). The shape of the metal during this heat treatment is the shape "remembered." The heat-treated metal is cooled to a temperature at which the martensite phase is stable, causing the austenite phase to transform to the martensite phase. The metal in the martensite phase is then plastically deformed, e.g. to facilitate the entry thereof into a patient's body. Subsequent heating of the deformed martensite phase to a temperature above the martensite to austenite transformation temperature causes the deformed martensite phase to transform to the austenite phase, and during this phase transformation the metal reverts back to its original shape if unrestrained. If restrained, the metal will remain martensitic until the restraint is removed.

Methods of using the shape memory characteristics of these alloys in medical devices intended to be placed within a patient's body present operational difficulties. For example, with shape memory alloys having a stable martensite temperature below body temperature, it is frequently difficult to maintain the temperature of the medical device containing such an alloy sufficiently below body temperature to prevent the transformation of the martensite phase to the austenite phase when the device was being inserted into a patient's body. With intravascular devices formed of shape memory alloys having martensite-to-austenite transformation temperatures well above body temperature, the devices can be introduced into a patient's body with little or no problem, but they must be heated to the martensite-to-austenite transformation temperature which is frequently high enough to cause tissue damage.

When stress is applied to a specimen of a metal such as Nitinol exhibiting superelastic characteristics at a temperature above which the austenite is stable (i.e. the temperature at which the transformation of martensite phase to the austenite phase is complete), the specimen deforms  
5 elastically until it reaches a particular stress level where the alloy then undergoes a stress-induced phase transformation from the austenite phase to the martensite phase. As the phase transformation proceeds, the alloy undergoes significant increases in strain but with little or no corresponding increases in stress. The strain increases while the stress remains essentially  
10 constant until the transformation of the austenite phase to the martensite phase is complete. Thereafter, further increases in stress are necessary to cause further deformation. The martensitic metal first deforms elastically upon the application of additional stress and then plastically with permanent residual deformation.

15

If the load on the specimen is removed before any permanent deformation has occurred, the martensitic specimen will elastically recover and transform back to the austenite phase. The reduction in stress first causes a decrease in strain. As stress reduction reaches the level at which the  
20 martensite phase transforms back into the austenite phase, the stress level in the specimen will remain essentially constant (but substantially less than the constant stress level at which the austenite transforms to the martensite) until the transformation back to the austenite phase is complete, i.e. there is significant recovery in strain with only negligible corresponding stress  
25 reduction. After the transformation back to austenite is complete, further stress reduction results in elastic strain reduction. This ability to incur significant strain at relatively constant stress upon the application of a load, and to recover from the deformation upon the removal of the load, is commonly referred to as superelasticity or pseudoelasticity. It is this property of the material which  
30 makes it useful in manufacturing tube cut self-expanding stents.

The prior art makes reference to the use of metal alloys having superelastic characteristics in medical devices which are intended to be



inserted or otherwise used within a patient's body. See for example, U.S. Patent No. 4,665,905 to Jervis and U.S. Patent No. 4,925,445 to Sakamoto et al. However, the prior art has yet to disclose any suitable tube-cut self-expanding stents. In addition, many of the prior art stents lacked the  
5 necessary rigidity or hoop strength to keep the body vessel open. In addition, many of the prior art stents have large openings at their expanded diameter. The smaller the openings are on an expanded stent, the more plaque or other deposits it can trap between the stent and the vessel wall. Trapping these deposits is important to the continuing health of the patient in that it helps  
10 prevent plaque prolapse into the vessel, restenosis of the vessel it is implanted into, and strokes caused by the release of embolic particles into the bloodstream.

One additional concern with stents and with other medical devices  
15 formed from superelastic materials, is that they may exhibit reduced radiopacity under X-ray fluoroscopy. To overcome this problem, it is common practice to attach markers, made from highly radiopaque materials, to the stent, or to use radiopaque materials in plating or coating processes. Those materials typically include gold, platinum, or tantalum. The prior art makes reference to these  
20 markers or processes in U.S. Patent No. 5,632,771 to Boatman et al., U.S. Patent No. 6,022,374 to Imran, U.S. Patent No. 5,741,327 to Frantzen, U.S. Patent No. 5,725,572 to Lam et al., and U.S. Patent No. 5,800,526 to Anderson et al. However, due to the size of the markers and the relative position of the materials forming the markers in the galvanic series versus the position of the  
25 base metal of the stent in the galvanic series, there is a certain challenge to overcome; namely, that of galvanic corrosion. In addition, typical markers are not integral to the stent and thus may interfere with the overall performance of the stent as well as become dislodged from the stent. Also, typical markers are used to indicate relative position within the lumen and not whether the device is  
30 in the deployed or undeployed position.

#### SUMMARY OF THE INVENTION

The present invention overcomes many of the disadvantages associated with reduced radiopacity exhibited by self-expanding stents, balloon-expandable stents, and other medical devices as briefly discussed above.

5           In accordance with one aspect, the present invention is directed to an intraluminal medical device. The intraluminal medical device comprises a substantially tubular member having open ends, and a first diameter for insertion into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel and at least one marker connected to at least one end of  
10 the substantially tubular member, the at least one marker comprising a marker housing and a marker insert.

          In accordance with another aspect, the present invention is directed to an intraluminal medical device. The intraluminal device comprises a thin-  
15 walled, substantially tubular member having open ends, and a first diameter for insertion into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel, the thin-walled tubular member comprising a superelastic alloy and at least one marker connected to at least one end of the thin-walled, substantially tubular member, the at least one marker comprising a marker  
20 housing and a marker insert.

          In accordance with another aspect, the present invention is directed to a stent. The stent comprises a thin-walled, substantially tubular member having open ends, and a first diameter for insertion into a lumen of a vessel and a  
25 second diameter for anchoring in the lumen of the vessel, the thin-walled tubular member comprising a superelastic alloy and at least one marker connected to at least one end of the thin-walled, substantially tubular member, the at least one marker comprising a marker housing and a marker insert.

30           In accordance with yet another aspect, the present invention is directed to a method of manufacturing an intraluminal medical device having improved radiopacity. The method comprises forming a substantially tubular lattice from a tubular member having first and second ends, a first diameter for insertion

into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel, the substantially tubular lattice being formed from a superelastic alloy forming at least one marker housing from the tubular member that is integral with the substantially tubular lattice, the marker housing defining a substantially elliptical opening and having a predefined curvature forming a marker insert having the same curvature as the substantially elliptical opening and seating the marker insert into the substantially elliptical opening.

The improved radiopacity intraluminal medical device of the present invention utilizes high radiopacity markers to ensure proper positioning of the device within a lumen. The markers comprise a housing which is integral to the device itself, thereby ensuring minimal interference with deployment and operation of the device. The markers also comprise a properly sized marker insert having a higher radiopacity than the material forming the device itself. The marker insert is sized to match the curvature of the housing thereby ensuring a tight and unobtrusive fit. The marker inserts are made from a material close in the galvanic series to the device material and sized to substantially minimize the effect of galvanic corrosion.

The improved radiopacity intraluminal medical device of the present invention provides for more precise placement and post-procedural visualization in a lumen by increasing the radiopacity of the device under X-ray fluoroscopy. Given that the marker housings are integral to the device, they are simpler and less expensive to manufacture than markers that have to be attached in a separate process.

The improved radiopacity intraluminal medical device of the present invention is manufactured utilizing a process which ensures that the marker insert is securely positioned within the marker housing. The marker housing is laser cut from the same tube and is integral to the device. As a result of the laser cutting process, the hole in the marker housing is conical in the radial direction with the outer surface diameter being larger than the inner surface diameter. The conical tapering effect in the marker housing is beneficial in

providing an interference fit between the marker insert and the marker housing to prevent the marker insert from being dislodged once the device is deployed. The marker inserts are loaded into a crimped device by punching a disk from annealed ribbon stock and shaping it to have the same radius of curvature as the marker housing. Once the disk is loaded into the marker housing, a coining process is used to properly seat the marker below the surface of the housing. The coining punch is also shaped to maintain the same radius of curvature as the marker housing. The coining process deforms the marker housing material to form a protrusion, thereby locking in the insert or disk.

10

#### BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other aspects of the present invention will best be appreciated with reference to the detailed description of the invention in conjunction with the accompanying drawings, wherein:

15

Figure 1 is a perspective view of an exemplary stent in its compressed state which may be utilized in conjunction with the present invention.

20

Figure 2 is a sectional, flat view of the stent shown in Figure 1.

Figure 3 is a perspective view of the stent shown in Figure 1 but showing it in its expanded state.

25

Figure 4 is an enlarged sectional view of the stent shown in Figure 3.

Figure 5 is an enlarged view of section of the stent shown in Figure 2.

30

Figure 6 is a view similar to that of Figure 2 but showing an alternate embodiment of the stent.

Figure 7 is a perspective view of the stent of Figure 1 having a plurality of markers attached to the ends thereof in accordance with the present invention.

5        Figure 8 is a cross-sectional view of a marker in accordance with the present invention.

Figure 9 is an enlarged perspective view of an end of the stent with the markers forming a substantially straight line in accordance with the present  
10    invention.

Figure 10 is a simplified partial cross-sectional view of a stent delivery apparatus having a stent loaded therein, which can be used with a stent made in accordance with the present invention.

15        Figure 11 is a view similar to that of Figure 10 but showing an enlarged view of the distal end of the apparatus.

Figure 12 is a perspective view of an end of the stent with the markers in a partially expanded form as it emerges from the delivery apparatus in  
20    accordance with the present invention.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

25        While the present invention may be used on or in connection with any number of medical devices, including stents, for ease of explanation, one exemplary embodiment of the invention with respect to self-expanding Nitinol stents will be described in detail. There is illustrated in Figures 1 and 2, a stent 100, which may be utilized in connection with the present invention. Figures 1  
30    and 2 illustrate the exemplary stent 100 in its unexpanded or compressed state. The stent 100 is preferably made from a superelastic alloy such as Nitinol. Most preferably, the stent 100 is made from an alloy comprising from about 50.0 percent (as used herein these percentages refer to weight

percentages) Ni to about 60 percent Ni, and more preferably about 55.8 percent Ni, with the remainder of the alloy being Ti. Preferably, the stent 100 is designed such that it is superelastic at body temperature, and preferably has an Af in the range from about 24° C to about 37° C. The superelastic design  
5 of the stent 100 makes it crush recoverable which, as discussed above, makes it useful as a stent or frame for any number of vascular devices in different applications.

Stent 100 is a tubular member having front and back open ends 102  
10 and 104 and a longitudinal axis 106 extending therebetween. The tubular member has a first smaller diameter, Figures 1 and 2, for insertion into a patient and navigation through the vessels, and a second larger diameter, Figures 3 and 4, for deployment into the target area of a vessel. The tubular member is made from a plurality of adjacent hoops 108, Figure 1 showing  
15 hoops 108(a) - 108(d), extending between the front and back ends 102 and 104. The hoops 108 include a plurality of longitudinal struts 110 and a plurality of loops 112 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form a substantially S or Z shape pattern. The loops 112 are curved, substantially semi-circular with symmetrical sections about  
20 their centers 114.

Stent 100 further includes a plurality of bridges 116 which connect adjacent hoops 108 and which can best be described in detail by referring to Figure 5. Each bridge 116 has two ends 118 and 120. The bridges 116 have  
25 one end attached to one strut and/or loop, and another end attached to a strut and/or loop on an adjacent hoop. The bridges 116 connect adjacent struts together at bridge to loop connection points 122 and 124. For example, bridge end 118 is connected to loop 114(a) at bridge to loop connection point 122, and bridge end 120 is connected to loop 114(b) at bridge to loop connection  
30 point 124. Each bridge to loop connection point has a center 126. The bridge to loop connection points are separated angularly with respect to the longitudinal axis. That is, the connection points are not immediately opposite each other. Essentially, one could not draw a straight line between the

connection points, wherein such line would be parallel to the longitudinal axis of the stent.

The above described geometry helps to better distribute strain  
5 throughout the stent, prevents metal to metal contact when the stent is bent, and minimizes the opening size between the struts, loops and bridges. The number of and nature of the design of the struts, loops and bridges are important factors when determining the working properties and fatigue life properties of the stent. It was previously thought that in order to improve the  
10 rigidity of the stent, that struts should be large, and therefore there should be fewer struts per hoop. However, it has now been discovered that stents having smaller struts and more struts per hoop actually improve the construction of the stent and provide greater rigidity. Preferably, each hoop has between twenty-four to thirty-six or more struts. It has been determined that a stent having a  
15 ratio of number of struts per hoop to strut length  $L$  (in inches) which is greater than four hundred has increased rigidity over prior art stents, which typically have a ratio of under two hundred. The length of a strut is measured in its compressed state parallel to the longitudinal axis 106 of the stent 100 as illustrated in Figure 1.

20

As seen from a comparison of Figures 2 and 3, the geometry of the stent 100 changes quite significantly as the stent 100 is deployed from its unexpanded state to its expanded state. As a stent undergoes diametric change, the strut angle and strain levels in the loops and bridges are affected.  
25 Preferably, all of the stent features will strain in a predictable manor so that the stent is reliable and uniform in strength. In addition, it is preferable to minimize the maximum strain experienced by struts loops and bridges, since Nitinol properties are more generally limited by strain rather than by stress. As will be discussed in greater detail below, the stent sits in the delivery system in its unexpanded state as shown in Figures 10 and 11. As the stent is deployed, it is  
30 allowed to expand towards its expanded state, as shown in Figure 3, which preferably has a diameter which is the same or larger than the diameter of the target vessel. Nitinol stents made from wire deploy in much the same manner,

and are dependent upon the same design constraints, as laser cut stents. Stainless steel stents deploy similarly in terms of geometric changes as they are assisted by forces from balloons or other devices.

5           In trying to minimize the maximum strain experienced by features of the stent, the present invention utilizes structural geometries which distribute strain to areas of the stent which are less susceptible to failure than others. For example, one of the most vulnerable areas of the stent is the inside radius of the connecting loops. The connecting loops undergo the most deformation of  
10 all the stent features. The inside radius of the loop would normally be the area with the highest level of strain on the stent. This area is also critical in that it is usually the smallest radius on the stent. Stress concentrations are generally controlled or minimized by maintaining the largest radii possible. Similarly, we want to minimize local strain concentrations on the bridge and bridge  
15 connection points. One way to accomplish this is to utilize the largest possible radii while maintaining feature widths which are consistent with applied forces. Another consideration is to minimize the maximum open area of the stent. Efficient utilization of the original tube from which the stent is cut increases stent strength and its ability to trap embolic material.

20

Many of these design objectives have been accomplished by an exemplary embodiment of the present invention, illustrated in Figures 1, 2 and 5. As seen from these figures, the most compact designs which maintain the largest radii at the loop to bridge connections are non-symmetric with respect  
25 to the centerline of the strut connecting loop. That is, loop to bridge connection point centers 126 are offset from the center 114 of the loops 112 to which they are attached. This feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Nitinol can withstand  
30 extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local



strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.

5           As seen in Figure 5, stent 100 comprises strut connecting loops 112 having a width W1, as measured at the center 114 parallel to axis 106, which are greater than the strut widths W2, as measured perpendicular to axis 106 itself. In fact, it is preferable that the thickness of the loops vary so that they are thickest near their centers. This increases strain deformation at the strut  
10 and reduces the maximum strain levels at the extreme radii of the loop. This reduces the risk of stent failure and allows one to maximize radial strength properties. This feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Nitinol can withstand  
15 extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. As stated above, this feature allows for maximum utilization of Ni-Ti or other material properties to enhance radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance  
20 entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.

As mentioned above, bridge geometry changes as a stent is deployed from its compressed state to its expanded state and vise-versa. As a stent  
25 undergoes diametric change, strut angle and loop strain is affected. Since the bridges are connected to either the loops, struts or both, they are affected. Twisting of one end of the stent with respect to the other, while loaded in the stent delivery system, should be avoided. Local torque delivered to the bridge ends displaces the bridge geometry. If the bridge design is duplicated around  
30 the stent perimeter, this displacement causes rotational shifting of the two loops being connected by the bridges. If the bridge design is duplicated throughout the stent, as in the present invention, this shift will occur down the length of the stent. This is a cumulative effect as one considers rotation of one

end with respect to the other upon deployment. A stent delivery system, such as the one described below, will deploy the distal end first, then allow the proximal end to expand. It would be undesirable to allow the distal end to anchor into the vessel wall while holding the stent fixed in rotation, then release  
5 the proximal end. This could cause the stent to twist or whip in rotation to equilibrium after it is at least partially deployed within the vessel. Such whipping action may cause damage to the vessel.

However, one exemplary embodiment of the present invention, as  
10 illustrated in Figures 1 and 2, reduces the chance of such events happening when deploying the stent. By mirroring the bridge geometry longitudinally down the stent, the rotational shift of the Z-sections or S-sections may be made to alternate and will minimize large rotational changes between any two points on a given stent during deployment or constraint. That is, the bridges  
15 connecting loop 108(b) to loop 108(c) are angled upwardly from left to right, while the bridges connecting loop 108(c) to loop 108(d) are angled downwardly from left to right. This alternating pattern is repeated down the length of the stent 100. This alternating pattern of bridge slopes improves the torsional characteristics of the stent so as to minimize any twisting or rotation of the  
20 stent with respect to any two hoops. This alternating bridge slope is particularly beneficial if the stent starts to twist in vivo. As the stent twists, the diameter of the stent will change. Alternating bridge slopes tend to minimize this effect. The diameter of a stent having bridges which are all sloped in the same direction will tend to grow if twisted in one direction and shrink if twisted  
25 in the other direction. With alternating bridge slopes this effect is minimized and localized.

The feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending  
30 requirements where large elastic strains are required. Nitinol, as stated above, can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti or other material properties to enhance

radial strength, to improve stent strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.

5

Preferably, stents are laser cut from small diameter tubing. For prior art stents, this manufacturing process led to designs with geometric features, such as struts, loops and bridges, having axial widths  $W_2$ ,  $W_1$  and  $W_3$ , respectively, which are larger than the tube wall thickness  $T$  (illustrated in Figure 3). When  
10 the stent is compressed, most of the bending occurs in the plane that is created if one were to cut longitudinally down the stent and flatten it out. However, for the individual bridges, loops and struts, which have widths greater than their thickness, there is a greater resistance to this in-plane bending than to out-of-plane bending. Because of this, the bridges and struts tend to twist,  
15 so that the stent as a whole may bend more easily. This twisting is a buckling condition which is unpredictable and can cause potentially high strain.

However, this problem has been solved in an exemplary embodiment of the present invention, as illustrated in Figures 1-5. As seen from these figures,  
20 the widths of the struts, hoops and bridges are equal to or less than the wall thickness of the tube. Therefore, substantially all bending and, therefore, all strains are "out-of-plane." This minimizes twisting of the stent which minimizes or eliminates buckling and unpredictable strain conditions. This feature is particularly advantageous for stents having large expansion ratios, which in  
25 turn requires them to have extreme bending requirements where large elastic strains are required. Nitinol, as stated above, can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti  
30 strength uniformity, to improve fatigue life by minimizing local strain levels, to allow for smaller open areas which enhance entrapment of embolic material, and to improve stent apposition in irregular vessel wall shapes and curves.

An alternate exemplary embodiment of a stent that may be utilized in conjunction with the present invention is illustrated in Figure 6. Figure 6 shows stent 200 which is similar to stent 100 illustrated in Figures 1-5. Stent 200 is made from a plurality of adjacent hoops 202, Figure 6 showing hoops 202(a) - 202(d). The hoops 202 include a plurality of longitudinal struts 204 and a plurality of loops 206 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form a substantially S or Z shape pattern. Stent 200 further includes a plurality of bridges 208 which connect adjacent hoops 202. As seen from the figure, bridges 208 are non-linear and curve between adjacent hoops. Having curved bridges allows the bridges to curve around the loops and struts so that the hoops can be placed closer together which in turn, minimizes the maximum open area of the stent and increases its radial strength as well. This can best be explained by referring to Figure 4. The above described stent geometry attempts to minimize the largest circle which could be inscribed between the bridges, loops and struts, when the stent is expanded. Minimizing the size of this theoretical circle, greatly improves the stent because it is then better suited to trap embolic material once it is inserted into the patient.

As mentioned above, it is preferred that the stent of the present invention be made from a superelastic alloy and most preferably made of an alloy material having greater than 50.5 atomic percentage Nickel and the balance Titanium. Greater than 50.5 atomic percentage Nickel allows for an alloy in which the temperature at which the martensite phase transforms completely to the austenite phase (the  $A_f$  temperature) is below human body temperature, and preferably is about 24° C to about 37°C, so that austenite is the only stable phase at body temperature.

In manufacturing the Nitinol stent, the material is first in the form of a tube. Nitinol tubing is commercially available from a number of suppliers, including Nitinol Devices and Components, Fremont CA. The tubular member is then loaded into a machine which will cut the predetermined pattern of the stent into the tube, as discussed above and as shown in the figures. Machines

for cutting patterns in tubular devices to make stents or the like are well known to those of ordinary skill in the art and are commercially available. Such machines typically hold the metal tube between the open ends while a cutting laser, preferably under microprocessor control, cuts the pattern. The pattern  
5 dimensions and styles, laser positioning requirements, and other information are programmed into a microprocessor which controls all aspects of the process. After the stent pattern is cut, the stent is treated and polished using any number of methods or combination of methods well known to those skilled in the art. Lastly, the stent is then cooled until it is completely martensitic,  
10 crimped down to its un-expanded diameter and then loaded into the sheath of the delivery apparatus.

As stated in previous sections of this application, markers having a radiopacity greater than that of the superelastic alloys may be utilized to  
15 facilitate more precise placement of the stent within the vasculature. In addition, markers may be utilized to determine when and if a stent is fully deployed. For example, by determining the spacing between the markers, one can determine if the deployed stent has achieved its maximum diameter and adjusted accordingly utilizing a tacking process. Figure 7 illustrates an  
20 exemplary embodiment of the stent 100 illustrated in Figures 1-5 having at least one marker on each end thereof. In a preferred embodiment, a stent having thirty-six struts per hoop can accommodate six markers 800. Each marker 800 comprises a marker housing 802 and a marker insert 804. The marker insert 804 may be formed from any suitable biocompatible material having a high  
25 radiopacity under X-ray fluoroscopy. In other words, the marker inserts 804 should preferably have a radiopacity higher than that of the material comprising the stent 100. The addition of the marker housings 802 to the stent necessitates that the lengths of the struts in the last two hoops at each end of the stent 100 be longer than the strut lengths in the body of the stent to  
30 increase the fatigue life at the stent ends. The marker housings 802 are preferably cut from the same tube as the stent as briefly described above. Accordingly, the housings 802 are integral to the stent 100. Having the

housings 802 integral to the stent 100 serves to ensure that the markers 800 do not interfere with the operation of the stent

Figure 8 is a cross-sectional view of a marker housing 802. The housing  
5 802 may be elliptical when observed from the outer surface as illustrated in Figure 7. As a result of the laser cutting process, the hole 806 in the marker housing 802 is conical in the radial direction with the outer surface 808 having a diameter larger than the diameter of the inner surface 810, as illustrated in Figure 8. The conical tapering in the marker housing 802 is beneficial in  
10 providing an interference fit between the marker insert 804 and the marker housing 802 to prevent the marker insert 804 from being dislodged once the stent 100 is deployed. A detailed description of the process of locking the marker insert 804 into the marker housing 802 is given below.

15 As set forth above, the marker inserts 804 may be made from any suitable material having a radiopacity higher than the superelastic material forming the stent or other medical device. For example, the marker insert 804 may be formed from niobium, tungsten, gold, platinum or tantalum. In the preferred embodiment, tantalum is utilized because of its closeness to nickel-  
20 titanium in the galvanic series and thus would minimize galvanic corrosion. In addition, the surface area ratio of the tantalum marker inserts 804 to the nickel-titanium is optimized to provide the largest possible tantalum marker insert, easy to see, while minimizing the galvanic corrosion potential. For example, it has been determined that up to nine marker inserts 804 having a diameter of  
25 0.010 inches could be placed at the end of the stent 100; however, these marker inserts 804 would be less visible under X-ray fluoroscopy. On the other hand, three to four marker inserts 804 having a diameter of 0.025 inches could be accommodated on the stent 100; however, galvanic corrosion resistance would be compromised. Accordingly, in the preferred embodiment, six tantalum  
30 markers having a diameter of 0.020 inches are utilized on each end of the stent 100 for a total of twelve markers 800.

The tantalum markers 804 may be manufactured and loaded into the housing utilizing a variety of known techniques. In the exemplary embodiment, the tantalum markers 804 are punched out from an annealed ribbon stock and are shaped to have the same curvature as the radius of the marker housing 802 as illustrated in Figure 8. Once the tantalum marker insert 804 is loaded into the marker housing 802, a coining process is used to properly seat the marker insert 804 below the surface of the housing 802. The coining punch is also shaped to maintain the same radius of curvature as the marker housing 802. As illustrated in Figure 8, the coining process deforms the marker housing 802 material to lock in the marker insert 804.

As stated above, the hole 806 in the marker housing 802 is conical in the radial direction with the outer surface 808 having a diameter larger than the diameter of the inner surface 810 as illustrated in Figure 8. The inside and outside diameters vary depending on the radius of the tube from which the stent is cut. The marker inserts 804, as stated above, are formed by punching a tantalum disk from annealed ribbon stock and shaping it to have the same radius of curvature as the marker housing 802. It is important to note that the marker inserts 804, prior to positioning in the marker housing 804, have straight edges. In other words, they are not angled to match the hole 806. The diameter of the marker insert 804 is between the inside and outside diameter of the marker housing 802. Once the marker insert 804 is loaded into the marker housing, a coining process is used to properly seat the marker insert 804 below the surface of the housing 802. In the preferred embodiment, the thickness of the marker insert 804 is less than or equal to the thickness of the tubing and thus the thickness or height of the hole 806. Accordingly, by applying the proper pressure during the coining process and using a coining tool that is larger than the marker insert 804, the marker insert 804 may be seated in the marker housing 802 in such a way that it is locked into position by a radially oriented protrusion 812. Essentially, the applied pressure, and size and shape of the housing tool forces the marker insert 804 to form the protrusion 812 in the marker housing 802. The coining tool is also shaped to maintain the same radius of curvature as the marker housing. As illustrated in Figure 8, the

protrusion 812 prevents the marker insert 804 from becoming dislodged from the marker housing.

5 It is important to note that the marker inserts 804 are positioned in and locked into the marker housing 802 when the stent 100 is in its unexpanded state. This is due to the fact that it is desirable that the tube's natural curvature be utilized. If the stent were in its expanded state, the coining process would change the curvature due to the pressure or force exerted by the coining tool.

10 As illustrated in Figure 9, the marker inserts 804 form a substantially solid line that clearly defines the ends of the stent in the stent delivery system when seen under fluoroscopic equipment. As the stent 100 is deployed from the stent delivery system, the markers 800 move away from each other and flower open as the stent 100 expands as illustrated in Figure 7. The change in  
15 the marker grouping provides the physician or other health care provider with the ability to determine when the stent 100 has been fully deployed from the stent delivery system.

It is important to note that the markers 800 may be positioned at other  
20 locations on the stent 100.

It is believed that many of the advantages of the present invention can be better understood through a brief description of a delivery apparatus for the stent, as shown in Figures 10 and 11. Figures 10 and 11 show a self-  
25 expanding stent delivery apparatus 10 for a stent made in accordance with the present invention. Apparatus 10 comprises inner and outer coaxial tubes. The inner tube is called the shaft 12 and the outer tube is called the sheath 14. Shaft 12 has proximal and distal ends. The proximal end of the shaft 12 terminates at a luer lock hub 16. Preferably, shaft 12 has a proximal portion 18  
30 which is made from a relatively stiff material such as stainless steel, Nitinol, or any other suitable material, and a distal portion 20 which may be made from a polyethylene, polyimide, Pellethane, Pebax, Vestamid, Cristamid, Grillamid or any other suitable material known to those of ordinary skill in the art. The two



portions are joined together by any number of means known to those of ordinary skill in the art. The stainless steel proximal end gives the shaft the necessary rigidity or stiffness it needs to effectively push out the stent, while the polymeric distal portion provides the necessary flexibility to navigate  
5 tortuous vessels.

The distal portion 20 of the shaft 12 has a distal tip 22 attached thereto. The distal tip 22 has a proximal end 24 whose diameter is substantially the same as the outer diameter of the sheath 14. The distal tip 22 tapers to a  
10 smaller diameter from its proximal end to its distal end, wherein the distal end 26 of the distal tip 22 has a diameter smaller than the inner diameter of the sheath 14. Also attached to the distal portion 20 of shaft 12 is a stop 28 which is proximal to the distal tip 22. Stop 28 may be made from any number of materials known in the art, including stainless steel, and is even more  
15 preferably made from a highly radiopaque material such as platinum, gold or tantalum. The diameter of stop 28 is substantially the same as the inner diameter of sheath 14, and would actually make frictional contact with the inner surface of the sheath. Stop 28 helps to push the stent out of the sheath during deployment, and helps keep the stent from migrating proximally into the sheath  
20 14.

A stent bed 30 is defined as being that portion of the shaft between the distal tip 22 and the stop 28. The stent bed 30 and the stent 100 are coaxial so that the distal portion 20 of shaft 12 comprising the stent bed 30 is located  
25 within the lumen of the stent 100. However, the stent bed 30 does not make any contact with stent 100 itself. Lastly, shaft 12 has a guidewire lumen 32 extending along its length from its proximal end and exiting through its distal tip 22. This allows the shaft 12 to receive a guidewire much in the same way that an ordinary balloon angioplasty catheter receives a guidewire. Such  
30 guidewires are well known in art and help guide catheters and other medical devices through the vasculature of the body.

Sheath 14 is preferably a polymeric catheter and has a proximal end terminating at a sheath hub 40. Sheath 14 also has a distal end which terminates at the proximal end 24 of distal tip 22 of the shaft 12, when the stent is in its fully un-deployed position as shown in the figures. The distal end of sheath 14 includes a radiopaque marker band 34 disposed along its outer surface. As will be explained below, the stent is fully deployed from the delivery apparatus when the marker band 34 is lined up with radiopaque stop 28, thus indicating to the physician that it is now safe to remove the apparatus 10 from the body. Sheath 14 preferably comprises an outer polymeric layer and an inner polymeric layer. Positioned between outer and inner layers is a braided reinforcing layer. Braided reinforcing layer is preferably made from stainless steel. The use of braided reinforcing layers in other types of medical devices can be found in U.S. Patent No. 3,585,707 issued to Stevens on June 22, 1971, U.S. Patent No. 5,045,072 issued to Castillo et al. on September 3, 1991, and U.S. Patent No. 5,254,107 issued to Soltesz on October 19, 1993.

Figures 10 and 11 illustrate the stent 100 as being in its fully un-deployed position. This is the position the stent is in when the apparatus 10 is inserted into the vasculature and its distal end is navigated to a target site. Stent 100 is disposed around stent bed 30 and at the distal end of sheath 14. The distal tip 22 of the shaft 12 is distal to the distal end of the sheath 14, and the proximal end of the shaft 12 is proximal to the proximal end of the sheath 14. The stent 100 is in a compressed state and makes frictional contact with the inner surface 36 of the sheath 14.

25

When being inserted into a patient, sheath 14 and shaft 12 are locked together at their proximal ends by a Tuohy Borst valve 38. This prevents any sliding movement between the shaft and sheath which could result in a premature deployment or partial deployment of the stent 100. When the stent 100 reaches its target site and is ready for deployment, the Tuohy Borst valve 38 is opened so that the sheath 14 and shaft 12 are no longer locked together.

30

The method under which the apparatus 10 deploys the stent 100 is readily apparent. The apparatus 10 is first inserted into the vessel until the radiopaque stent markers 800 (leading 102 and trailing 104 ends, see Figure 7) are proximal and distal to the target lesion. Once this has occurred the physician would open the Tuohy Borst valve 38. The physician would then grasp hub 16 of shaft 12 so as to hold it in place. Thereafter, the physician would grasp the proximal end of the sheath 14 and slide it proximal, relative to the shaft 12. Stop 28 prevents the stent 100 from sliding back with the sheath 14, so that as the sheath 14 is moved back, the stent 100 is pushed out of the distal end of the sheath 14. As stent 100 is being deployed the radiopaque stent markers 800 move apart once they come out of the distal end of sheath 14. Stent deployment is complete when the marker 34 on the outer sheath 14 passes the stop 28 on the inner shaft 12. The apparatus 10 can now be withdrawn through the stent 100 and removed from the patient.

15

Figure 12 illustrates the stent 100 in a partially deployed state. As illustrated, as the stent 100 expands from the delivery device 10, the markers 800 move apart from one another and expand in a flower like manner.

20

Although shown and described is what is believed to be the most practical and preferred embodiments, it is apparent that departures from specific designs and methods described and shown will suggest themselves to those skilled in the art and may be used without departing from the spirit and scope of the invention. The present invention is not restricted to the particular constructions described and illustrated, but should be constructed to cohere with all modifications that may fall within the scope of the appended claims.

25

## WHAT IS CLAIMED IS:

1. An intraluminal medical device comprising:  
a substantially tubular member having open ends, and a first  
5 diameter for insertion into a lumen of a vessel and a second diameter for  
anchoring in the lumen of the vessel; and  
at least one marker connected to at least one end of the  
substantially tubular member, the at least one marker comprising a  
marker housing and a marker insert having a radius of curvature equal  
10 to the radius of curvature of the substantially tubular marker.
2. The intraluminal medical device according to Claim 1, wherein the  
intraluminal medical device comprises a superelastic alloy.
- 15 3. The intraluminal medical device according to Claim 2, wherein the  
superelastic alloy comprises from about 50.0 percent to about 60  
percent Nickel and the remainder Titanium.
4. The intraluminal medical device according to Claim 1, wherein the  
20 marker housing comprises the same material as the intraluminal medical  
device and is integral thereto, thereby forming a unitary structure.
5. The intraluminal medical device according to Claim 4, wherein the  
marker insert comprises a material having a radiopacity higher than that  
25 of the material comprising the intraluminal medical device.
6. The intraluminal medical device according to Claim 5, wherein the  
marker insert comprises Tantalum.
- 30 7. The intraluminal medical device according to Claim 6, wherein the  
marker insert is secured in the marker housing by frictional, locking  
engagement.

8. The intraluminal medical device according to claim 7, wherein the marker insert is secured in the marker housing by a protruding ridge.

9. An intraluminal medical device comprising:

5 a thin-walled, substantially tubular member having open ends, and a first diameter for insertion into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel, the thin-walled tubular member comprising a superelastic alloy; and

10 at least one marker connected to at least one end of the thin-walled, substantially tubular member, the at least one marker comprising a marker housing and a marker insert having a radius of curvature equal to the radius of curvature of the substantially tubular marker.

15 10. The intraluminal medical device according to Claim 9, wherein the marker housing comprises the same material as the intraluminal medical device and is integral thereto, thereby forming a unitary structure.

20 11. The intraluminal medical device according to Claim 10, wherein the marker housing defines a substantially elliptical opening having a predetermined curvature.

25 12. The intraluminal medical device according to Claim 11, wherein the marker insert comprises a material having a radiopacity higher than that of the material comprising the intraluminal medical device.

13. The intraluminal medical device according to Claim 12, wherein the marker insert comprises Tantalum.

30 14. The intraluminal medical device according to Claim 13, wherein the marker insert has a curvature equal to that of the curvature of the opening in the marker housing.

15. The intraluminal medical device according to Claim 14, wherein the marker insert has a diameter of 0.02 inches.

16. The intraluminal medical device according to Claim 15, wherein the marker insert is secured in the marker housing by frictional, locking engagement.

17. The intraluminal medical device according to claim 16, wherein the marker insert is secured in the marker housing by a protruding ridge.

18. A stent comprising:

a thin-walled, substantially tubular member having open ends, and a first diameter for insertion into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel, the thin-walled tubular member comprising a superelastic alloy; and

at least one marker connected to at least one end of the thin-walled, substantially tubular member, the at least one marker comprising a marker housing and a marker insert having a radius of curvature equal to the radius of curvature of the substantially tubular marker.

19. The stent according to Claim 18, wherein the marker housing comprises the same material as the stent and is integral thereto, thereby forming a unitary structure.

20. The stent according to Claim 19, wherein the marker housing defines a substantially elliptical open having a predetermined curvature.

21. The stent according to Claim 20, wherein the marker insert comprises a material having a radiopacity higher than that of the material comprising the stent.

22. The stent according to Claim 21, wherein the marker insert comprises Tantalum.

23. The stent according to Claim 22, wherein the marker insert has a curvature equal to that of the curvature of the opening in the marker housing.

5

24. The stent according to Claim 23, wherein the marker insert has a diameter of 0.02 inches.

10

25. The stent according to Claim 24, wherein the marker insert is secured in the marker housing by frictional, locking engagement.

26. The intraluminal medical device according to claim 25, wherein the marker insert is secured in the marker housing by a protruding ridge.

15

27. The stent according to Claim 18, further comprising six markers attached to each end of the thin-walled, substantially tubular member.

28. A method of manufacturing an intraluminal medical device having improved radiopacity comprising:

20

forming a substantially tubular lattice from a tubular member having first and second ends, a first diameter for insertion into a lumen of a vessel and a second diameter for anchoring in the lumen of the vessel, the substantially tubular lattice being formed from a superelastic alloy;

25

forming at least one marker housing from the tubular member that is integral with the substantially tubular lattice, the marker housing defining a substantially elliptical opening and having a predefined radius of curvature;

30

forming a marker insert having the same radius of curvature as the substantially elliptical opening; and

seating the marker insert into the substantially elliptical opening.

29. The method of manufacturing an intraluminal medical device according to Claim 28, wherein the substantially elliptical opening has an inside and outside diameter.

5 30. The method of manufacturing an intraluminal medical device according to Claim 29, wherein the step of forming a marker insert comprises punching the marker insert from annealed ribbon stock having a high radiopacity, the marker insert having a diameter between the inside and outside diameter of the substantially elliptical opening.

10


31. The method of manufacturing an intraluminal medical device according to Claim 30, wherein the step of seating the marker insert into the substantially elliptical opening comprises:

15 loading the punched marker insert into the hole of the marker housing; and

coining the punched marker insert with a predefined pressure utilizing a coining tool such that the punched marker insert is forced below the surface of the marker housing and the marker housing deforms to form a protruding ridge.


20






2/11


FIG. 2



3/11




4/11




5/11


**FIG. 5**



**FIG. 6**




7/11




**FIG. 7**

8/11

**FIG. 8**




9/11



10/11

**FIG. 10**



**FIG. 11**





FIG. 12



## INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 02/09297

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L31/02 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 33534 A (BEYAR MORDECHAY ; BEYAR RAFAEL (IL); DOR OFER (IL); GLOBERMAN OREN) 18 September 1997 (1997-09-18) page 2, line 25 - page 3, line 6 page 8, line 13 - line 21 figures claims	1-31
X	EP 0 894 481 A (SCHNEIDER USA INC) 3 February 1999 (1999-02-03) paragraphs '0004!', '0029! claims	1-31
X	US 6 129 754 A (KANESAKA NOZOMU ET AL) 10 October 2000 (2000-10-10) column 4, line 1 - line 10 figures claims	1-31



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

26 July 2002

Date of mailing of the international search report

05/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Thornton, S

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 02/09297

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 945 107 A (APPLIED VASCULAR ENG INC) 29 September 1999 (1999-09-29) paragraphs '0005!', '0037!', '0046!', '0064!'-'0067! figures claims ---	1,4-7
X	WO 99 30643 A (SURFACE GENESIS INC) 24 June 1999 (1999-06-24) figures claims ---	1-31
X	EP 0 895 760 A (SORIN BIOMEDICA CARDIO SPA) 10 February 1999 (1999-02-10) paragraph '0023! figures claims ---	1-31
X	US 5 741 327 A (FRANTZEN JOHN J) 21 April 1998 (1998-04-21) column 7, line 49 -column 8, line 31 figures claims ---	1-31
X	WO 95 03010 A (COOK INC) 2 February 1995 (1995-02-02) page 13, line 4 - line 12 figures claims ---	1-31
P,X	WO 02 15820 A (ANGIOMED AG ;BRIEST ARNE (DE); LOMBARDI SYLVIE (DE); SUPPER WOLFGA) 28 February 2002 (2002-02-28) figures claims -----	1-31

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 02/09297

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9733534	A	18-09-1997	US 6334871 B1 AU 2208797 A EP 0891166 A1 WO 9733534 A1 US 6402777 B1	01-01-2002 01-10-1997 20-01-1999 18-09-1997 11-06-2002
EP 0894481	A	03-02-1999	US 6340367 B1 EP 0894481 A2 JP 2000060975 A US 2002082683 A1 US 6251135 B1	22-01-2002 03-02-1999 29-02-2000 27-06-2002 26-06-2001
US 6129754	A	10-10-2000	NONE	
EP 0945107	A	29-09-1999	EP 0945107 A2	29-09-1999
WO 9930643	A	24-06-1999	US 6022374 A AU 1920099 A WO 9930643 A1	08-02-2000 05-07-1999 24-06-1999
EP 0895760	A	10-02-1999	IT T0970729 A1 EP 0895760 A1	08-02-1999 10-02-1999
US 5741327	A	21-04-1998	US 6293966 B1	25-09-2001
WO 9503010	A	02-02-1995	AU 693779 B2 AU 6015194 A CA 2144305 A1 DE 69330132 D1 DE 69330132 T2 EP 0662806 A1 ES 2157977 T3 JP 8507243 T WO 9503010 A1 US 5632771 A US 6409752 B1	09-07-1998 20-02-1995 02-02-1995 17-05-2001 15-11-2001 19-07-1995 01-09-2001 06-08-1996 02-02-1995 27-05-1997 25-06-2002
WO 0215820	A	28-02-2002	AU 7981901 A WO 0215820 A2	04-03-2002 28-02-2002